Resonant Capital Advisors LLC Purchases 319 Shares of Danaher Co. (NYSE:DHR)

Resonant Capital Advisors LLC lifted its position in shares of Danaher Co. (NYSE:DHR) by 2.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,902 shares of the conglomerate’s stock after purchasing an additional 319 shares during the period. Resonant Capital Advisors LLC’s holdings in Danaher were worth $2,988,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Fairfield Bush & CO. increased its holdings in Danaher by 10.9% in the first quarter. Fairfield Bush & CO. now owns 4,840 shares of the conglomerate’s stock valued at $1,420,000 after purchasing an additional 475 shares during the period. Zions Bancorporation N.A. increased its stake in shares of Danaher by 19.3% in the first quarter. Zions Bancorporation N.A. now owns 2,468 shares of the conglomerate’s stock valued at $724,000 after buying an additional 400 shares during the period. Covestor Ltd raised its position in shares of Danaher by 76.8% during the first quarter. Covestor Ltd now owns 495 shares of the conglomerate’s stock worth $145,000 after acquiring an additional 215 shares during the last quarter. NewEdge Advisors LLC lifted its stake in shares of Danaher by 14.1% in the first quarter. NewEdge Advisors LLC now owns 31,530 shares of the conglomerate’s stock worth $9,248,000 after acquiring an additional 3,897 shares during the period. Finally, Bridgewater Associates LP boosted its holdings in Danaher by 135.9% in the first quarter. Bridgewater Associates LP now owns 35,270 shares of the conglomerate’s stock valued at $10,346,000 after acquiring an additional 20,320 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Barclays raised their price target on shares of Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 10th. Raymond James raised their target price on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. HSBC raised Danaher from a “hold” rating to a “buy” rating and boosted their price target for the company from $250.00 to $280.00 in a research note on Wednesday. Citigroup boosted their target price on shares of Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Six research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $268.27.

Danaher Stock Down 0.6 %

NYSE:DHR traded down $1.32 during trading hours on Friday, hitting $235.04. 1,367,008 shares of the company traded hands, compared to its average volume of 2,709,515. Danaher Co. has a one year low of $182.09 and a one year high of $259.00. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. The company has a market cap of $174.06 billion, a PE ratio of 36.80, a PEG ratio of 3.64 and a beta of 0.83. The firm’s 50-day simple moving average is $249.09 and its 200-day simple moving average is $229.90.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. The company had revenue of $6.41 billion during the quarter, compared to the consensus estimate of $6.10 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. Danaher’s revenue was down 10.2% on a year-over-year basis. During the same period last year, the business posted $2.87 earnings per share. Equities analysts predict that Danaher Co. will post 7.62 earnings per share for the current year.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be paid a $0.27 dividend. The ex-dividend date is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a dividend yield of 0.46%. Danaher’s payout ratio is presently 16.90%.

Insider Transactions at Danaher

In related news, SVP Daniel Raskas sold 23,757 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares in the company, valued at approximately $9,601,704. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,957 shares of company stock worth $8,265,802. 11.10% of the stock is owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.